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Undifferentiated pleomorphic sarcoma (formerly known as malignant fibrous histiocytoma: MFH) is 
a relatively rare primary malignant bone tumor first described by Norman and Feldman as a 
malignant histiocytoma.1 It comprises approximately 6 % of all bone tumors.2, 3 It is reported that the 
osteosarcoma adjuvant or neoadjuvant chemotherapeutic regimen is beneficial4 and a good 
pathological response predicted better disease-free survival.5 Caffeine is a xanthine analogue that 
has a biochemical modulating effect as an inhibitor of DNA repair, and may inhibit post-replication 
repair of sublethally damaged DNA.6, 7 Caffeine-potentiated chemotherapy has been administered to 
patients with high-grade bone and soft tissue sarcomas since 1989, because caffeine enhances the 
cytocidal effects of anticancer drugs through the inhibition of DNA-repair. Approximately 15% of 
primary malignant bone tumors involve the pelvic girdle.8 Periacetabular lesions are the most 
difficult site to reconstruct because of the complicated anatomical structure and complication rates 
including deep infection (12–47%), implant dislocation (2–22%), or local recurrence (28–35%) is 
still high in pelvic lesions.9-13 
In this study, we present a case of high-grade pleomorphic sarcoma involving the right acetabulum, 
which was successfully treated with curettage and a bone graft after complete remission following 
caffeine-potentiated chemotherapy. The patient and her parents were informed that her data would be 
submitted for publication and gave their consent. 
Case report 
A 14–year-old Japanese female patient was referred to our university hospital with pain in the right 
hip that had been present for 2 weeks after she slipped and fell on an icy road. The patient was 
previously diagnosed with multiple neurofibromatoses (Neurofibromatosis type1; NF1) in her 
childhood, but had no other disorders. The physical examination revealed no soft tissue swelling or 
mass around the hip joint, despite her limp. A plain radiograph of the pelvis showed an osteolytic 
lesion around the right acetabulum (Fig. 1–a). Computed tomography (CT) showed the lucent 
expansile lesion at the acetabulum (Fig. 2–a). Magnetic resonance images (MRI) of the lesion 
showed low intensity in the T1–weighted images (Fig. 3–a) and mixed iso and high intensities in the 
T2–weighted images (Fig. 3–b), and the tumor was highly enhanced by Gadolinium (Gd) (Fig. 3–c). 
There was no abnormal soft tissue mass. Technetium–99m and Thallium–201 scintigrams revealed 
area of strong accumulation in the right acetabulum (Fig. 4–a). Distant metastasis was not detected. 
Open biopsy was performed, and the tumor was diagnosed as high-grade undifferentiated 
pleomorphic sarcoma (Fig. 5–a, b, c). Immunohistochemical analysis revealed that αSMA (Fig. 5–c), 
CD31, CD68, and vimentin were focally positive, and Cam 5.2, AE1/3, HHF35, CD34, and S100 
were negative. Five courses of intra-arterial administration of cisplatin (120 mg/m2, for 4 hours) and 
doxorubicin (30 mg/m2/day for 2 days) combined with caffeine (1.5 g/m2/day for 3 days 
continuously) and 2 courses of intravenous ifosfamide (3 g/m2/day for 3 days) and etoposide (60 
mg/m2/day for 3 days) combined with caffeine (1.5 g/m2/day for 3 days continuously) were 
performed at three weeks intervals. Preoperative chemotherapy yielded a dramatic patient response. 
A plain radiograph of the pelvis (Fig. 1–a) and a CT showed a sclerotic change of the cortex (Fig. 
2–b). MRI showed that the tumor size was unchanged following chemotherapy in the T1–weighted 
images (Fig. 3–d). The signal intensity in the T2–weighted images changed to high intensity (Fig. 
3–e), and the Gd–enhanced images revealed the weak marginal enhancement around the tumor (Fig. 
3–f). The Thallium–201 scan revealed no accumulation on the right acetabulum (Fig. 4–b). 
Thereafter, we performed a second multi-sampling biopsy to confirm whether the viable tumor cells 
still existed. Microscopically, no viable tumor cells were detected, and total tumor necrosis was 
expected. We additionally performed one course of intravenous administration of ifosfamide and 
etoposide combined with caffeine. 
We proposed to the patient’s legal guardians that the treatment options were wide excision and 
pelvic reconstruction, hemipelvectomy, thorough curettage in conjunction with artificial bone graft, 
and heavy ion radiotherapy. After careful discussion, the patient’s guardians chose thorough 
curettage combined with artificial bone graft to preserve the patient’s normal limb function. Seven 
months after the initial diagnosis, the patient underwent surgery. We made a small incision and 
created a 3 × 4 cm bony window. Intraoperative frozen sections revealed no viable tumor cells. We 
proceeded to perform a thorough curettage using high speed-burr with the adjuvant use of phenol 
and ethanol. The cavity was filled with artificial bone paste (α-tricalcium phosphate, BIOPEX; 
Mitsubishi Materials Corporation, Tokyo, Japan) impregnated with 30 mg of doxorubicin as a local 
adjuvant treatment to prevent local recurrence. In the permanent section, no viable tumor cell was 
seen after surgery (Fig. 5–b). The patient underwent two courses of postoperative chemotherapy, 
consisting of cisplatin and doxorubicin combined with caffeine, and ifosfamide and etoposide 
combined with caffeine. The patient was permitted to place partial weight on the right leg 3 weeks 
after surgery. Full weight-bearing was permitted 2 months after surgery. The patient has been free of 
disease for 49 months after surgery. Although the artificial bone has not been replaced by newly 
formed bone, incorporation with the host bone has been obtained (Fig. 1–c). Moreover, the patient 
has been highly satisfied with the normal activities of her right lower limb. 
Discussion 
In this case, caffeine combined chemotherapy resulted in the complete remission of high-grade 
undifferentiated pleomorphic sarcoma of the pelvis, and rendered it possible to perform minimum 
invasive surgery to preserve limb function. Moreover, the tumor has not recurred 36 months after 
surgery. To our knowledge, no other attempt at curettage with chemotherapy for high-grade bone 
sarcoma has been reported to date. 
High-grade undifferentiated pleomorphic sarcoma is a relatively rare bone neoplasm that occurs in 
all age groups.2, 3 Several reports have described the effectiveness of neoadjuvant treatment with a 
regime similar to osteosarcoma.4 Improvements in imaging techniques, chemotherapy and surgical 
techniques has resulted in more limb-saving surgeries over the past three decades for patients with 
osteosarcoma. The recent literatures showed that the response rate of chemotherapy and the 
5-year-survival rate was reported to be 56–62% and 66-76%, respectively.13, 14 Capanna R, et al. 
reported that the 5-year survival rate of patients with MFH improved from 28% to 57% by 
administrating chemotherapy with surgical treatment.9 Picci P, et al. reported that a good 
pathological response correlated with better disease-free survival with a survival rate that was not 
different between osteosarcoma and MFH patients, although the patient response rate was 
significantly worse than in patients with osteosarcoma.5 We found only two reported cases of a 
malignant transformation of a neurofibromatous bone lesion to malignant fibrous histiocytoma.15, 16 
One patient exhibited irradiation-induced malignant transformation15 and the other patient had not 
undergone irradiation.16 In this case, no neurofibromatous tissue was observed in the tumor and no 
neurofibromatous bone lesion was detected at other sites. Chouwdhry M, et al. reported the 
association of NF1 with malignant bone tumors. They identified 8 of 2900 patients with a primary 
malignant bone tumor who had coexisting NF1.17 The histological diagnoses were four cases of 
osteosarcoma, four cases of spindle cell sarcoma and one case of Ewing’s sarcoma. Although the 
increased risk of bone sarcoma was estimated eight times that of the normal population, they found 
that the prognoses of these patients were favorable compared to patients who developed soft tissue 
sarcomas in association with NF1. 
Previously we reported the effectiveness of caffeine-potentiated chemotherapy for bone and soft 
tissue sarcomas in several studies.18, 19 In particular, this treatment induced a response rate of more 
than 90% in osteosarcoma patients and facilitated a reduction in the surgical margin for a majority of 
the patients who achieved a markedly favorable response.18 
The incidence of primary malignant bone tumor involving the pelvic girdle account for 
approximately 15% of primary malignant bone tumors.8 Periacetabular lesions are the most difficult 
site to reconstruct because of the complicated anatomical structure. Although a variety of 
reconstruction methods have been developed including custom-made prosthesis,10, 20 saddle 
prosthesis,11, 12 hip transposition,21 massive allograft,22, 23 recycling tumor-bearing autografts 
autoclaved,24 irradiated 25 or frozen by liquid nitrogen,26 and a bone graft-prosthesis composite,27 the 
resulting limb-function remains unsatisfactory. Complication rates including deep infection 
(12–47%), implant dislocation (2–22%), or local recurrence (28–35%) are still high in pelvic 
lesions9–12 and result in poor implant–related survival (42%).20 Moreover, any reconstruction 
methods following a wide excision severely diminish limb function, even if a marginal excision is 
performed. The pelvis is a technically demanding and challenging site. To our knowledge, this is the 
first report of successful treatment with curettage in conjunction with chemotherapy for high-grade 
undifferentiated pleomorphic sarcoma in the acetabulum. 
In this case, we implanted an artificial bone graft impregnated with 30 mg of doxorubicin. 
Although the effectiveness of the anti-cancer drug loaded artificial bone has not been clarified, there 
are few reports concerned about this approach.28, 29 We aimed to reduce the risk of local recurrence 
by this procedure. 
Jaffe, et al. reported the clinical outcome of the patients with osteosarcoma treated by 
chemotherapy without surgical extirpation of the primary tumor.30 Although they indicated this 
therapy for patients who showed clinical, radiographic, and histological responses, only 3 of 31 
patients were cured by the administration of chemotherapy alone. In addition, the inclusion of four 
additional patients who underwent extirpation of the primary tumor without disease recurrence, and 
in whom no viable tumor was found in the resected specimens, may increase the number of patients 
who were potentially cured with chemotherapy to 7 patients (23%). They concluded that the results 
of their study did not justify the adoption of the current forms of chemotherapy as exclusive 
treatments for osteosarcoma. Although long-term follow-up examination is necessary in the present 
case to define the indications of this treatment, we suggest adapting this treatment when complete 
disappearance of abnormal accumulation is observed on Thallium-201 scan, no enhancement of the 
tumor on Gd-enhanced MRI, and no viable cells in the second biopsy specimen are obtained, and 
when the patient strongly desires and consents to receive this treatment after careful discussion.    
In conclusion, the caffeine-potentiated chemotherapy showed total necrosis in this case and 
enabled us to perform the most conservative function-preserving surgery. The precise evaluation of 
preoperative chemotherapy effects with a Thalium–210 scan, MRI and biopsy is required to apply 
this procedure, but long-term follow-up period is necessary to define the indications. This approach 
will provide a greater benefit to patients with pelvic osteosarcoma. 
 
No benefits in any form have been received or will be received from a commercial party related 
directly or indirectly to the subject of this article. 
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Figure legends: 
Fig. 1. a AP radiograph on admission of the patient revealed an osteolytic lesion at the right 
acetabulum, b Radiograph after preoperative chemotherapy showed a sclerotic change of the cortex. 
c Radiograph taken at 49 months after surgery shows stable artificial bone graft without evidence of 
tumor recurrence. 
 
 Fig. 2. a Computed tomography (CT) on admission of the patient revealed the lucent expansile 
lesion at the acetabulum and the thinning of the cortex. b CT after preoperative chemotherapy 
showed a sclerotic change in the cortex. 
 
Fig. 3. a Coronal T1–weighted magnetic resonance imaging (MRI) (TR 500 ms, TE 5 ms) scan on 
admission revealed low intensity. b T2–weighted MRI (TR 3250 ms, TE 100 ms) images taken at the 
time of admission showed areas of mixed iso and high intensities. c T1–weighted gadolinium 
(Gd)–enhanced MRI (TR 180 ms, TE 1.4 ms) taken on admission of the patient showed strong 
enhancement at the tumor. d T1–weighted MRI (TR 500 ms, TE 5 ms) after preoperative 
chemotherapy showed areas of low intensity and the size of tumor was unchanged. e T2–weighted 
MRI (TR 3250 ms, TE 100 ms) showed regions of high intensity. f T1–weighted Gd–enhanced MRI 
(TR 180 ms, TE 1.4 ms) showed only weak marginal enhancement around the tumor. 
 
Fig. 4. a Thallium–201 scintigrams at the time of patient admission showed areas of 
high-accumulation at the right acetabulum (black arrow). b Thallium–201 scintigrams after 
preoperative chemotherapy showed no accumulation at the right acetabulum. 
 Fig. 5. a, b Histological biopsy analysis revealed an atypical and pleomorphic morphology, and large, 
bizarre nuclei. (hematoxylin and eosin stain, magnification a:100×, b:40×), c Immunohistochemical 
analysis of αSMA was focally positive (magnification 100×). d Specimen of surgery revealed 
complete necrosis (hematoxylin and eosin stain, magnification 100×). 
 
 
